These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2116585)

  • 1. What is cost-effectiveness analysis?
    Evans DB
    Med J Aust; 1990 Aug; 153(S1):S7-9. PubMed ID: 2116585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of treating mild-to-moderate hypertension: a reappraisal.
    Kawachi I; Malcolm LA
    J Hypertens; 1991 Mar; 9(3):199-208. PubMed ID: 1851782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of hypertension treatment--a review of methodological issues.
    Johannesson M; Jönsson B
    Health Policy; 1991 Sep; 19(1):55-77. PubMed ID: 10117392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the estimation of cost-effectiveness ratios.
    Johannesson M
    Health Policy; 1995 Mar; 31(3):225-9. PubMed ID: 10142618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the decision rules of cost-effectiveness analysis.
    Johannesson M; Weinstein MC
    J Health Econ; 1993 Dec; 12(4):459-67. PubMed ID: 10131756
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparing cost-effectiveness analyses of anti-hypertensive drug therapy for decision making: mission impossible?
    Mullins CD; Blak BT; Akhras KS
    Value Health; 2002; 5(4):359-71. PubMed ID: 12102698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of basing health-care resource allocations on cost-utility analysis in the presence of externalities.
    Labelle RJ; Hurley JE
    J Health Econ; 1992 Oct; 11(3):259-77. PubMed ID: 10122539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of cost-effectiveness analyses.
    Hurley S
    Med J Aust; 1990 Aug; 153(S1):S20-3. PubMed ID: 2116583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pressure to treat and pressure to cost: a review of cost-effectiveness analysis.
    Fletcher A
    J Hypertens; 1991 Mar; 9(3):193-8. PubMed ID: 1851781
    [No Abstract]   [Full Text] [Related]  

  • 10. Incremental cost-effectiveness ratios (ICERs): the silence of the lambda.
    Gafni A; Birch S
    Soc Sci Med; 2006 May; 62(9):2091-100. PubMed ID: 16325975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of age on the cost-effectiveness of hypertension treatment: an analysis of randomized drug trials.
    Johannesson M
    Med Decis Making; 1994; 14(3):236-44. PubMed ID: 7934710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be?
    Birch S; Gafni A
    J Health Econ; 1992 Oct; 11(3):279-96. PubMed ID: 10122540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compliance, quality of life, and cost effectiveness.
    Stason WB
    Curr Hypertens Rep; 1999 Dec; 1(6):471-4. PubMed ID: 10981107
    [No Abstract]   [Full Text] [Related]  

  • 14. An economic evaluation of the 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of mild-to-moderate hypertension in Greece.
    Stafilas PC; Sarafidis PA; Lasaridis AN; Aletras VH; Niakas DA
    Am J Hypertens; 2005 Sep; 18(9 Pt 1):1233-40; discussion 1241-2. PubMed ID: 16182115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of hypertension treatment.
    Ménard J
    Clin Exp Hypertens; 1996; 18(3-4):399-413. PubMed ID: 8743030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness ratios: in a league of their own.
    Birch S; Gafni A
    Health Policy; 1994 May; 28(2):133-41. PubMed ID: 10136058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Geriatric hypertension therapy: a guide to cost-effectiveness.
    Wright JT
    Geriatrics; 1988 Aug; 43(8):55-62. PubMed ID: 3136056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antihypertensive therapy: how to evaluate the benefits.
    Zanchetti A
    Am J Cardiol; 1997 May; 79(10A):3-8; discussion 47-8. PubMed ID: 9186060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Renal Denervation Therapy for Treatment-Resistant Hypertension: A Best Case Scenario.
    Chowdhury EK; Reid CM; Zomer E; Kelly DJ; Liew D
    Am J Hypertens; 2018 Sep; 31(10):1156-1163. PubMed ID: 30010694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacoeconomic considerations in the management of hypertension.
    Pardell H; Tresserras R; Armario P; Hernández del Rey R
    Drugs; 2000; 59 Suppl 2():13-20; discussion 39-40. PubMed ID: 10678593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.